March 10, 2021 07:00 AM ESTUpdated March 12, 01:32 PM
R&D
Coronavirus

Eli Lil­ly tops up pos­i­tive PhI­II da­ta for its Covid-19 an­ti­body com­bo at ‘the op­ti­mal dose’

John Carroll

Editor & Founder

Eli Lil­ly has added an­oth­er brick in the wall of pos­i­tive da­ta as­sem­bled for its com­bo an­ti­body ther­a­py for Covid-19.

Its BLAZE-1 Phase III study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

A service from the Financial Times